A Randomized Open Label Multicenter Phase 3 Trial Comparing S1 Generic With Capecitabine in Patients With Metastatic Breast Cancer
Phase of Trial: Phase III
Latest Information Update: 25 Jan 2018
At a glance
- Drugs Capecitabine (Primary) ; Gimeracil/oteracil/tegafur (Primary)
- Indications Breast cancer
- Focus Registrational; Therapeutic Use
- 21 Jan 2018 Status changed from active, no longer recruiting to discontinued.
- 03 Jan 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
- 03 Jan 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.